Heterogeneous Treatment Effects of GLP-1RA on Kidney Outcomes in Patients with Type 2 Diabetes.
GLP-1 diabetes drugs protect kidneys most in patients at highest risk, enabling doctors to target this therapy to those who benefit most.
This large target trial emulation (n=28,547) using causal survival forest methods and KFRE risk stratification demonstrates GLP-1RA kidney protection is heterogeneous and concentrated in high-risk patients (HR 0.70 in highest KFRE quarter vs no benefit in lowest). Clinical features driving the most kidney benefit include lower eGFR, faster eGFR decline, higher albuminuria, and higher HbA1c — providing actionable personalized prescribing guidance.
What the study was
- Study design
- Target trial emulation, active comparator new-user cohort study (n=28,547; Stockholm registry 2008-2021)
- Population
- Adults with type 2 diabetes initiating GLP-1RA or DPP-4i in Stockholm County (2008-2021)
- Sample size
- 28547
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Kidney international
Why it surfaced
Large target trial emulation (n=28K) using causal survival forests showing GLP-1RA kidney protection concentrated in highest-risk patients. Actionable: GLP-1RA should prioritize those with lowest eGFR, highest albuminuria, fastest eGFR decline. Carrero JJ group (Karolinska Institutet).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.